Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00450021 · ClinicalTrials.gov registry record · Phase 1

Imaging of Cannabinoid Receptors Using New Radioactive Tracer

A Phase 1 study of Healthy, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT00450021: Completed Phase 1 study of Healthy, sponsored by National Institute of Mental Health (NIMH).

NCT00450021 is a Phase 1 study of Healthy that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 25 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00450021, a Phase 1 study of Healthy, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This study will test a new radioactive tracer, \[(11)C\]MePPEP, for use in positron emission tomography (PET) imaging. The tracer is used to visualize cannabinoid receptors, proteins in the brain that mediate a variety of natural chemicals. These receptors may be important in behavioral diseases such as addiction, obesity and psychiatric diseases. Healthy normal volunteers between 18 and 65 years of age may be eligible for this study. Ten participants undergo whole body PET imaging to determine where the \[(11)C\]MePPEP tracer is distributed in the body in order to calculate radiation exposure from the tracer. Another 10 subjects undergo brain imaging with \[(11)C\]MePPEP to measure cannabinoid receptors in the brain. All participants are evaluated with a medical history and physical examination, blood and urine tests and an electrocardiogram (ECG) before scanning. They then have a PET scan. For this procedure, a catheter (plastic tube) is placed in a vein in the arm through which the tracer is injected. A special mask is fitted to the head and attached to the bed to help keep the head in place during the scan. Subjects undergoing brain imaging also have a catheter placed in an artery in the wrist from which blood samples are collected during the procedure. The scan lasts about 2 to 2.5 hours. Subjects undergoing brain imaging also have magnetic resonance imaging (MRI) within 1 year of the PET scan. For MRI, the subject lies on a bed that moves into the tubular scanner, wearing earplugs to protect the ears from loud noises that occur during the scan. The procedure takes about 1 hour.

Conditions Studied

Interventions

  • DRUG [(11)C] MePPEP

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2007-03-19
Phase Phase 1

What the Registry Record Tells You About NCT00450021

The ClinicalTrials.gov registry entry for NCT00450021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [(11)C] MePPEP is the first listed.

NCT00450021 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00450021 about?

NCT00450021 is a clinical study titled "Imaging of Cannabinoid Receptors Using New Radioactive Tracer". This study will test a new radioactive tracer, \[(11)C\]MePPEP, for use in positron emission tomography (PET) imaging. The tracer is used to visualize cannabinoid receptors, proteins in the brain that mediate a variety of natural chemicals. These receptors may be important in behavioral diseases suc...

What is the current status of trial NCT00450021?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-03-19.

What conditions does trial NCT00450021 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00450021?

The interventions under investigation include: [(11)C] MePPEP (DRUG).

Who is sponsoring clinical trial NCT00450021?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00450021 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.